Chromosome 1q21 abnormalities in multiple myeloma
Abstract Gain of chromosome 1q (+ 1q) is one of the most common recurrent cytogenetic
abnormalities in multiple myeloma (MM), occurring in approximately 40% of newly …
abnormalities in multiple myeloma (MM), occurring in approximately 40% of newly …
Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review
K Neupane, GG Fortuna, R Dahal, T Schmidt… - Blood cancer …, 2024 - nature.com
Extra copies of chromosome 1q21 (+ 1q: gain= 3 copies, amp>= 4 copies) are associated
with worse outcomes in multiple myeloma (MM). This systematic review assesses the current …
with worse outcomes in multiple myeloma (MM). This systematic review assesses the current …
Prospective evaluation of whole-body MRI versus FDG PET/CT for lesion detection in participants with myeloma
Purpose To compare disease detection of myeloma using contemporary whole-body (WB)
MRI and fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT protocols and to correlate …
MRI and fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT protocols and to correlate …
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)
MRD2STOP is a pragmatic trial evaluating maintenance therapy cessation guided by
measurable residual disease (MRD) negativity in multiple myeloma (MM). Eligible patients …
measurable residual disease (MRD) negativity in multiple myeloma (MM). Eligible patients …
Myeloma Genome Project Panel is a comprehensive targeted genomics panel for molecular profiling of patients with multiple myeloma
Purpose: We designed a comprehensive multiple myeloma targeted sequencing panel to
identify common genomic abnormalities in a single assay and validated it against known …
identify common genomic abnormalities in a single assay and validated it against known …
The role of 1q abnormalities in multiple myeloma: Genomic insights, clinical implications, and therapeutic challenges
ZM Avigan, CS Mitsiades, A Laganà - Seminars in Hematology, 2024 - Elsevier
Chromosome 1q copy number variations, collectively termed+ 1q, are one of the most
common cytogenetic abnormalities in multiple myeloma. 1q abnormalities are associated …
common cytogenetic abnormalities in multiple myeloma. 1q abnormalities are associated …
In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma
RM Rifkin, CL Costello, RE Birhiray… - Future …, 2024 - Taylor & Francis
Aim: To compare the effectiveness of in-class transition to all-oral ixazomib-lenalidomide-
dexamethasone (IRd) following parenteral bortezomib (V)-based induction versus continued …
dexamethasone (IRd) following parenteral bortezomib (V)-based induction versus continued …
Risk-adapted treatment for multiple myeloma: assessing the current potential and a roadmap for the future
S Zanwar, S Kumar - Leukemia & Lymphoma, 2024 - Taylor & Francis
Over the past two decades, new agents for multiple myeloma (MM) have significantly
improved patient outcomes, particularly for those with standard-risk disease, who now have …
improved patient outcomes, particularly for those with standard-risk disease, who now have …
Distinct pathway activities are associated with prognosis and response to bortezomib-containing treatment in MCL1-M based molecular subtypes of multiple myeloma
Y Yang, S Jiang, H Du, J Tang, P Xiao, Y Wu, J Li… - Annals of …, 2024 - Springer
Multiple myeloma (MM) is the second most prevalent hematological malignancy and
remains incurable with remarkable heterogeneity in prognosis and treatment response …
remains incurable with remarkable heterogeneity in prognosis and treatment response …
Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma
Cytogenetic abnormalities influence the prognosis of multiple myeloma (MM). How these
abnormalities associate with overall survival (OS) in European Americans (EAs) and African …
abnormalities associate with overall survival (OS) in European Americans (EAs) and African …